Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EQ

EQ - Equillium Inc Stock Price, Fair Value and News

$2.06+0.02 (+0.98%)
Market Closed

49/100

EQ

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

49/100

EQ

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EQ Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EQ Price Action

Last 7 days

-4.6%

Last 30 days

1.0%

Last 90 days

45.1%

Trailing 12 Months

402.4%

EQ RSI Chart

EQ Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EQ Valuation

Market Cap

125.4M

Price/Earnings (Trailing)

-5.11

Price/Sales (Trailing)

1.24

EV/EBITDA

-1.64

Price/Free Cashflow

-5.45

EQ Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EQ Fundamentals

EQ Revenue

Revenue (TTM)

41.1M

EQ Earnings

Earnings (TTM)

-24.4M

Earnings Growth (Yr)

-60.3K%

Earnings Growth (Qtr)

26.29%

EQ Profitability

EBT Margin

-28.25%

Return on Equity

-78.92%

Return on Assets

-70.76%

Free Cashflow Yield

-18.36%

EQ Investor Care

Shares Dilution (1Y)

71.87%

Diluted EPS (TTM)

-0.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202437.9M42.6M45.9M41.1M
202320.8M25.9M31.0M36.1M
202200015.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Equillium Inc

EQ
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
 CEO
 WEBSITEhttps://equilliumbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES47

Equillium Inc Frequently Asked Questions

EQ is the stock ticker symbol of Equillium Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri May 01 2026, market cap of Equillium Inc is 125.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri May 01 2026, EQ's PE ratio (Price to Earnings) is -5.11 and Price to Sales (PS) ratio is 1.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EQ PE ratio will change depending on the future growth rate expectations of investors.